Patent Law Weblog
recent posts
- USPTO Moves to Protect Design Rights for Digital Innovations
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
about
Month: July 2010
-
Technology Transfer Tactics will be offering an audioconference entitled "The Future of Patenting in Biomedicine" on August 26, 2010 from 1:00 – 2:30 PM (EDT). Patent Docs author Dr. Kevin Noonan of McDonnell Boehnen Hulbert & Berghoff LLP and Professor Chris Holman of the University of Missouri-Kansas City School of Law will take an in-depth…
-
The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "Patent Term Extension: The Next Chapter" on Thursday, August 5, 2010 beginning at 2:00 PM (EDT). The IPO webinar will present a panel of experts — including the patent prosecutor who first discovered a separate calculation error by the U.S. Patent and Trademark…
-
Technology Transfer Tactics will be offering an audioconference entitled "Bilski: The Impact of the Final Decision on University TTOs" on August 17, 2010 from 1:00 – 2:30 PM (EDT). Charles Macedo of Amster, Rothstein and Ebenstein, LLP; Scott Alter of Faegre & Benson; and Dr. Ronald Kudla, the executive director of intellectual property, technology transfer,…
-
The Center for Business Intelligence (CBI) will be holding its 5th Summit on Biosimilars and Follow-on Biologics on October 18-19, 2010 in Washington, DC. At the Summit, CBI's faculty will offer presentations on the following topics: • FDA's implementation of the biosimilar approval pathway — What to anticipate and how to be prepared (keynote panel…
-
By Andrew Williams — On Wednesday, in Sun Pharm. Indus., Ltd. v. Eli Lilly & Co., the Federal Circuit affirmed a finding that claims of Lilly's U.S. Patent No. 5,464,826 ("the '826 patent) were invalid for obviousness-type double patenting over U.S. Patent No. 4,808,614 ("the '614 patent"). The '614 patent claims gemcitabine, and methods of…
-
By James DeGiulio — Medicis Pharmaceuticals Settles Solodyn Litigation with Mylan Medicis Pharmaceuticals Corporation has reached settlement and license agreements with Mylan, Inc., thus resolving the patent litigation over Solodyn. In 2009, Medicis brought suit against Mylan and several drug companies in the U.S. District Court for the District of Delaware, alleging infringement of U.S.…
-
By Donald Zuhn — Earlier this month, the House of Representatives passed the "2010 Supplemental Appropriations Act" (H.R. 4899) after tacking an additional $22.8 billion onto the Senate version of the bill, which called for $45.5 billion in discretionary funding for FY 2010. The bill would provide, inter alia, $37.12 billion for U.S. troops in…
-
By Kevin E. Noonan — The idea of a "golden age," almost always some time in the past, is a recurrent theme in history, literature, and myth. It is also the unspoken theme in Abbott's principal brief filed earlier this week in Therasense Inc. v. Becton Dickinson & Co., and that Golden Age has an…
-
By Sydney Kokjohn — Last week, the U.S. Patent and Trademark Office celebrated the one-year anniversary of its e-Office Action (e-OA) program. So far, the program has electronically notified patent applicants on more than 850,000 Office communications and reduced Patent Office paper usage by more than 9.2 million pages. A pilot version of the…
-
By Ignacio Sanchez Echagüe — The Argentine Patent Office (Instituto Nacional de la Propiedad Industrial, INPI) has issued Regulation No. 147/2010, which restricts the ability of applicants to file divisional applications once substantive examination has begun. The regulation, which went into effect on July 16, 2010, allows applicants to file divisional applications until notice…
Patent Docs 